Design Space Development for Lyophilization Using DOE and Process Modeling - Develop a relevant design space without full factorial DoE. - BioPharm International

ADVERTISEMENT

Design Space Development for Lyophilization Using DOE and Process Modeling
Develop a relevant design space without full factorial DoE.


BioPharm International
Volume 23, Issue 9

DESIGN SPACE DEVELOPMENT: A CASE STUDY

Thermal Characterization and Initial Lyophilization Development


Table 1. Initial/target lyophilization cycle for monoclonal antibody X
The MAb discussed in this case study was formulated in a solution containing a buffer, a sugar lyoprotectant, and a surfactant. To understand the thermal characteristics of this formulation, we performed freeze-drying microscopy experiments.6 The collapse temperature was determined to be –14 C (Figure 3), suggesting that product temperature during primary drying must be maintained well below –14 C.


Figure 4. Process inputs and outputs for lyophilization design space development
During the early process development phase for this molecule, an initial lyophilization cycle (Table 1) was implemented based on prior lyophilization experience with similar products and literature knowledge.7–9 Briefly, the approach consisted of experiments to accomplish primary drying in a reasonable duration while maintaining product temperature well below the collapse temperature.

Risk Assessments for the Lyophilization Unit Operation


Figure 5. Risk ranking and filtering tool (CQA = critical quality attribute)
The process inputs and outputs for lyophilization generally are well known and are shown in Figure 4.7–9 To identify the parameters that must be characterized, we used the risk ranking tool depicted in Figure 5.10 The main and interaction effect scores for each parameter were assigned based on a mechanistic understanding of the lyophilization process and experience with products and equipment. The overall severity score was then used to decide the nature of characterization for the parameter.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
Author Guidelines
Source: BioPharm International,
Click here